Details

Autor(en) / Beteiligte

• Chemaly, Roy F
• Ullmann, Andrew J
• Stoelben, Susanne
• Richard, Marie Paule
• Bornhäuser, Martin
• Groth, Christoph
• Einsele, Hermann
• Silverman, Margarida
• Mullane, Kathleen M
• Brown, Janice
• Nowak, Horst
• Kölling, Katrin
• Stobernack, Hans P
• Lischka, Peter
• Zimmermann, Holger
• Rübsamen-Schaeff, Helga
• Champlin, Richard E
• Ehninger, Gerhard

Titel

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

Ist Teil von

• The New England journal of medicine, 2014-05, Vol.370 (19), p.1781-1789

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Letermovir is an antiviral with activity against CMV. In patients undergoing allogeneic hematopoietic-cell transplantation, the rate of prophylaxis failure with letermovir (240 mg per day) was 29%, as compared with 64% with placebo. Toxicity was similar for letermovir and placebo. Cytomegalovirus (CMV) disease that results from CMV replication through reactivation or new infection is a serious, potentially life-threatening condition in immunocompromised patients. This is especially true for recipients of allogeneic hematopoietic-cell transplants 1 , 2 ; CMV viremia occurs in 50 to 60% of these patients and may progress to CMV disease. 3 The standard of care for treatment of CMV infection or disease has typically been intravenous ganciclovir or its oral prodrug, valganciclovir, or alternatively, intravenous foscarnet or cidofovir. 4 Although efficacious, these therapies are associated with clinically significant drug-specific effects, including myelosuppression (neutropenia or thrombocytopenia with ganciclovir, valganciclovir, and cidofovir) and renal . . .